Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ALX Oncology Holdings Inc. - Common Stock (NQ:ALXO)

1.552 +0.182 (+13.31%)
Streaming Delayed Price Updated: 12:19 PM EST, Jan 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ALX Oncology Holdings Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
ALX Oncology Holdings Inc (NASDAQ:ALXO) Reports Q2 2025 Results with Wider Loss but Strong Clinical Progress ↗
ALX Oncology reports Q2 2025 results with a net loss of $25.9M, wider than expected, but shares dip only slightly. Clinical progress, including evorpacept data and ALX2004 trials, remains key focus.... 
Via Chartmill
News headline image
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Holdings's Earnings: A Preview ↗
 
Via Benzinga
News headline image
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
What's Next: ALX Oncology Holdings's Earnings Preview ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
Top movers in Tuesday's after hours session ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
News headline image
Which stocks are moving on Thursday? ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Top movers in Thursday's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
This Zscaler Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
 
Via Benzinga
News headline image
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
From ALX Oncology
Via GlobeNewswire
News headline image
Earnings Scheduled For March 6, 2025 ↗
 
Via Benzinga
News headline image
ALX Oncology to Host Virtual R&D Day on March 5, 2025
Company leadership and external key opinion leaders to highlight clinical program progress and provide business and financial updates 
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
From ALX Oncology
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.